Announcement • Sep 02

United Therapeutics Corporation Announces Fda Acceptance of Supplemental New Drug Application for Nebulized Tyvaso to Treat Idiopathic Pulmonary Fibrosis

United Therapeutics Corporation announced that the FDA has accepted the supplemental New Drug Application (sNDA) for nebulized Tyvaso (treprostinil) Inhalation Solution to treat idiopathic pulmonary fibrosis (IPF). United Therapeutics anticipates the agency's review to be complete in late April 2027. Nebulized Tyvaso has not been approved by the FDA for IPF and remains investigational for this indication. Nebulized Tyvaso combines direct lung delivery with multimodal activity across fibrotic, vascular, and inflammatory pathways that are central to IPF, with the potential to help address a significant unmet need for this life-threatening disease. The filing was based on positive results from the phase 3 TETON-1 and TETON-2 studies. Combined analyses of TETON-1 and TETON-2 met the primary efficacy endpoint, with nebulized Tyvaso demonstrating statistically significant superiority over placebo for the change in absolute forced vital capacity (FVC) by 111.8 mL (Hodges-Lehmann estimate, 95% confidence interval, 79.7 to 144.0 mL; p). The effects diminish over the minimum recommended dosing interval of 4 hours; treatment timing can be adjusted for planned activities. While there are long-term data on use of treprostinil by other routes of administration, nearly all clinical experience with inhaled treprostinil has been on a background of an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor. The controlled clinical experience with TYVASO was limited to 12 weeks in duration. Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study with TYVASO establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and WHO Group 3 connective tissue disease (22%). TYVASO is a pulmonary and systemic vasodilator. In patients with low systemic arterial pressure, TYVASO may produce symptomatic hypotension. TYVASO inhibits platelet aggregation and increases the risk of bleeding. Co-administration of a cytochrome P450 (CYP) 2C8 enzyme inhibitor (e.g., gemfibrozil) may increase exposure (both Cmax and AUC) to treprostinil. Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. Increased exposure is likely to increase adverse events associated with treprostinil administration, whereas decreased exposure is likely to reduce clinical effectiveness. Like other inhaled prostaglandins, TYVASO may cause acute bronchospasm. Patients with asthma or chronic obstructive pulmonary disease (COPD), or other bronchial hyperreactivity, are at increased risk for bronchospasm. Ensure that such patients are treated optimally for reactive airway disease prior to and during treatment with TYVASO. The concomitant use of TYVASO with diuretics, antihypertensives, or other vasodilators may increase the risk of symptomatic hypotension. Human pharmacokinetic studies with an oral formulation of treprostinil (treprostinil diolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor, gemfibrozil, increases exposure (both Cmax and AUC) to treprostinil. Co-administration of the CYP2C8 enzyme inducer, rifampin, decreases exposure to treprostinil. It is unclear if the safety and efficacy of treprostinil by the inhalation route are altered by inhibitors or inducers of CYP2C8. Limited case reports of treprostinil use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. However, pulmonary arterial hypertension is associated with an increased risk of maternal and fetal mortality. There are no data on the presence of treprostinil in human milk, the effects on the breastfed infant, or the effects on milk production. Safety and effectiveness in pediatric patients have not been established. Across clinical studies used to establish the effectiveness of TYVASO in patients with PAH and PH ILD, 268 (47.8%) patients aged 65 years and over were enrolled. The treatment effects and safety profile observed in geriatric patients were similar to younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of hepatic, renal, or cardiac dysfunction, and of concomitant diseases or other drug therapy. In a 12-week, placebo-controlled study (TRIUMPH I) of 235 patients with PAH (WHO Group 1 and nearly all NYHA Functional Class III), the most common adverse reactions seen with TYVASO in =4% of PAH patients and more than 3% greater than placebo were cough (54% vs 29%), headache (41% vs 23%), throat irritation/pharyngolaryngeal pain (25% vs 14%), nausea (19% vs 11%), flushing (15% vs <1%), and syncope (6% vs <1%). In addition, adverse reactions occurring in =4% of patients were dizziness and diarrhea. In a 16-week, placebo-controlled study (INCREASE) of 326 patients with PH-ILD (WHO Group 3), adverse reactions with TYVASO were similar to the experience in studies of PAH.

United Therapeutics Corporation Stock Price

UTHR Share Price Performance

UTHR Community Narratives

UTHR: Recent Clinical Success Will Drive Expansion Into New Pulmonary Markets

Patent Expirations And Biosimilar Pressures Will Diminish Value

Advances In PAH And Organ Manufacturing Will Fuel Market Expansion

Patent Expirations And Biosimilar Pressures Will Diminish Value

Advances In PAH And Organ Manufacturing Will Fuel Market Expansion

UTHR: Recent Clinical Success Will Drive Expansion Into New Pulmonary Markets

Trending Discussion

Recently Updated Narratives

UTHR: Mixed Pulmonary Franchise Outlook And Lung Platform Progress Will Shape Expectations

UTHR: Transplant Platform And Organ Manufacturing Advances Will Drive Future Stock Upside

UTHR: IPF Lung Data Will Drive Future Pulmonary Franchise Repricing

Snowflake Analysis

United Therapeutics Corporation Key Details

About UTHR

Recent UTHR News & Updates

United Therapeutics Initiates $477 Million Repurchase Completing $2 Billion Authorization

FDA Review Underway for United Therapeutics’ Tyvaso Expansion in Pulmonary Fibrosis

United Therapeutics Corporation Announces Fda Acceptance of Supplemental New Drug Application for Nebulized Tyvaso to Treat Idiopathic Pulmonary Fibrosis

Recent updates

United Therapeutics Corporation Competitors

Pfizer

Danaher

Vertex Pharmaceuticals

Bristol-Myers Squibb